Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 2 · 66.7%

Three doses HPV vaccine vs control

Overall local/injection site adverse events at 15‐day · 10‐ to 26‐year‐old males

Three doses HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with control (high certainty).

1 finding from 1 review

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes only
RR 1.12 [1.06, 1.18]
1 study · 3895 participants
High

Nonavalent HPV vaccine vs quadrivalent HPV vaccine

Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males

Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).

1 finding from 1 review

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes only
RR 1.07 [1.05, 1.08]
3 studies · 15863 participants
High

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.22 [0.13, 0.38]
2 studies · 435 participants
Moderate